CURO Biosciences Secures ₹16 cr for advancing saliva-based cancer detection tech – ET HealthWorld
New Delhi : CURO Biosciences Private Limited, operating under the name ErlySign, has raised ₹16 crore in pre-Series A funding from investor Ashish Kacholia. The funding, facilitated by DerivativeSaint, a private equity and venture capital advisory firm, highlights the company’s focus on early cancer detection. This development positions CURO Biosciences to contribute to the global … Read more